Mirae Asset Global Investments Co. Ltd. Purchases 254,475 Shares of Novo Nordisk A/S (NYSE:NVO)

Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 53.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 729,965 shares of the company’s stock after acquiring an additional 254,475 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Novo Nordisk A/S were worth $63,183,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in NVO. AQR Capital Management LLC raised its position in shares of Novo Nordisk A/S by 110.5% during the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after acquiring an additional 9,012 shares during the last quarter. Mather Group LLC. raised its position in shares of Novo Nordisk A/S by 4.3% during the third quarter. Mather Group LLC. now owns 5,835 shares of the company’s stock worth $695,000 after acquiring an additional 243 shares during the last quarter. Aprio Wealth Management LLC raised its position in shares of Novo Nordisk A/S by 4.7% during the third quarter. Aprio Wealth Management LLC now owns 5,148 shares of the company’s stock worth $613,000 after acquiring an additional 230 shares during the last quarter. Tealwood Asset Management Inc. raised its position in shares of Novo Nordisk A/S by 0.8% during the third quarter. Tealwood Asset Management Inc. now owns 14,116 shares of the company’s stock worth $1,681,000 after acquiring an additional 116 shares during the last quarter. Finally, Park Place Capital Corp bought a new stake in Novo Nordisk A/S in the third quarter valued at about $119,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.1 %

NVO stock opened at $82.60 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The stock has a market capitalization of $370.65 billion, a P/E ratio of 26.73, a P/E/G ratio of 0.93 and a beta of 0.45. The business has a 50-day moving average of $93.12 and a 200-day moving average of $112.54. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NVO. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.